Evidence map›Paper›PMID 39681352›Full record

ArticleMolecular pharmaceutics2025

Synthesis and Characterization of Thallium-Texaphyrin Nanoparticles and Their Assessment as Potential Delivery Systems for Auger Electron-Emitting

Katarzyna M Wulfmeier, Miffy H Y Cheng, Zhongli Cai, Samantha Y A Terry, Vincenzo Abbate, Philip J Blower, Gang Zheng, Raymond M Reilly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katarzyna M WulfmeierDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, U.K.ORCID 0000-0003-4742-4399
Miffy H Y ChengPrincess Margaret Cancer Centre, University Health Network, Toronto M5G 1L7, Canada.ORCID 0000-0002-0261-4642
Zhongli CaiDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 1A1, Canada.ORCID 0000-0002-8937-4943
Samantha Y A TerryDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, U.K.
Vincenzo AbbateInstitute of Pharmaceutical Sciences, King's College London, London SE19NH, U.K.ORCID 0000-0002-3300-0520
Philip J BlowerDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, U.K.ORCID 0000-0001-6290-1590
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, Toronto M5G 1L7, Canada.
Raymond M ReillyPrincess Margaret Cancer Centre, University Health Network, Toronto M5G 1L7, Canada.ORCID 0000-0003-1038-7993

Funding

Wellcome TrustWellcome Trust 212885/Z/18/Z
6 · The paper itself

Abstract

Thallium-201 is an Auger electron-emitting radionuclide with significant potential for targeted molecular radiotherapy of cancer. It stands out among other Auger electron emitters by releasing approximately 37 Auger and Coster-Kronig electrons per decay, which is one of the highest numbers in its category. It has also a convenient half-life of 73 h, a stable daughter product, established production methods, and demonstrated high

Indexed as

NanoparticlesPorphyrinsCell Line, TumorChelating AgentsDrug Delivery SystemsElectronsHumansNeoplasmsRadiopharmaceuticalsThalliumThallium RadioisotopesChelating AgentsPorphyrinsRadiopharmaceuticalstexaphyrinThalliumThallium Radioisotopes201TlAuger electronsradiation nanomedicinestargeted radionuclide therapytexaphyrin-lipid

Identifiers

PMID39681352
PMCPMC11707725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.